The Research Triangle Park, N.C.-based company posted losses of $14.7 million, or 11¢ per share, on sales of $1.6 million for the 3 months ended June 30, seeing losses down 81.9%.
Losses per share were just in line with the 11¢ consensus on Wall Street, where analysts were expecting to see revenue of $1.6 million for the quarter.
“We are very pleased with the progress we made during the quarter on our key strategic priorities, including the steps taken towards achieving 510(k) clearance for the Senhance by the end of 2017. We are also encouraged by the continued momentum in clinical utilization in Europe, and now globally with our sale in Japan. In addition, we have been able to leverage the open architecture of the Senhance to incorporate cutting edge technologies into the platform, setting a new standard for minimally invasive robotic surgery,” prez & CEO Todd Pope said in a press release.
TransEnterix shares rose 3% today, closing at 65¢.
Registration is open for DeviceTalks Boston! Join us on June 5-6, 2019, as we explore the trends and technology that are shaping the future of the medical device industry.